# US 2025/0144093 A1 · Pyruvate kinase activators for use in treating blood disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144093 A1
- Document ID: US20250144093A1
- Status: Published application
- Kind: A1
- Application number: 18/882,884
- Filed: 2024-09-12
- Published: 2025-05-08
- Earliest claimed: 2017-08-15
- Assignees: Agios Pharmaceuticals, Inc.
- Applicants: Agios Pharmaceuticals, Inc.
- Inventors: Giovanni CIANCHETTA; Tao Liu; Anil Kumar Padyana; Zhihua Sui; Zhenwei Cai; Dawei Cui; Jingjing Ji
- Web page: https://patentgrep.com/patent/US20250144093A1

## CPC

- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 35/00: Antineoplastic agents
- C07D 241/36: condensed with carbocyclic rings or ring systems
- C07D 513/14: Ortho-condensed systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.

## Claims

### Claim at position 1

-42. (canceled)

### Claim 43

A compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen, an optionally substituted alkyl, an optionally substituted haloalkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, —ORo1, —C(═O)Rc1, or a nitrogen protecting group; wherein:
Rol is hydrogen, optionally substituted alkyl, or an oxygen protecting group;
Rc1 is optionally substituted alkyl or —N(Rcn)2, wherein each instance of
Rcn is independently hydrogen, —C1-6 alkyl, or a nitrogen protecting group;
Q is an optionally substituted 5 or 6-membered monocyclic heteroaryl;
Ra and Rb are each independently hydrogen, a halogen, —CN, —NO2, —N3, an optionally substituted alkyl, —ORo3, —N(Rn1)2, —C(═O)N(Rn1)2, or —C(═O)Rc2; or alternatively Ra and Rb can be taken together with the carbon atom to which they are attached to form an optionally substituted cycloalkyl or an optionally substituted heterocyclyl; wherein:
each instance of Rn1 is independently hydrogen, an optionally substituted —C1-C6 alkyl, or a nitrogen protecting group;
Ro3 is hydrogen, an optionally substituted —C1-C6 alkyl, or an oxygen protecting group; and
Rc2 is an optionally substituted —C1-C6 alkyl; and
Rj and Rk are each independently hydrogen, a halogen, —CN, —ORo7, —N(Rn5)2, —N(Rn5)C(═O)Rc5, —C(═O)N(Rn5)2, —C(═O)Rc5, —C(═O)ORo7, —SRjs, —S(═O)2Rjs, —S(═O)Rjs, or an optionally substituted —C1-C6 alkyl; or alternatively Rj and Rk can be taken together with the carbon atom to which they are attached to form C═O, an optionally substituted C1-C6 monocyclic cycloalkyl ring, or an optionally substituted C3-C6 monocyclic heterocyclyl ring; wherein:
each instance of Rn5 is independently hydrogen, an optionally substituted —C1-C6 alkyl, —ORo8, or a nitrogen protecting group, wherein Ro8 is hydrogen, an optionally substituted —C1-C6 alkyl, or an oxygen protecting group;
each instance of Ro7 is independently hydrogen, an optionally substituted —C1-C6 alkyl, or an oxygen protecting group;
each instance of Ro5 is independently an optionally substituted —C1-C6 alkyl;
each instance of Rjs is independently an optionally substituted —C1-C6 alkyl, an optionally substituted C6-12 aryl, an optionally substituted heteroaryl, or a sulfur protecting group;
each instance of Rp is independently hydrogen, a halogen, —CN, —NO2, —N3, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted heteroaryl, —ORo6, —SRs2, —N(Rn3)2, —C(═O)N(Rn3)2, —N(Rn3)C(═O)Ro4, —C(═O)Ro4, —C(═O)ORo6, —OC(═O)Ro4, —S(═O)Rs2, —S(═O)2Rs2, —S(═O)ORo6, —OS(═O)Ro4, —S(═O)2ORo6, —OS(═O)2Ro4, —S(═O)N(Rn3)2, —S(═O)2N(Rn3)2, —N(Rn3)S(═O)R2, —N(Rn3)S(═O)2Rs2, —N(Rn3)C(═O)ORo6, —OC(═O)N(Rn3)2, —N(Rn3)C(═O)N(Rn3)2, —N(Rn3)S(═O)N(Rn3)2, —N(Rn3)S(═O)2N(Rn3)2, —N(Rn3)S(═O)ORo6, —N(Rn3)S(═O)2ORo6, —OS(═O)N(Rn3)2, or —OS(═O)2N(Rn3)2; or alternatively two instances of Rp attached to the same or adjacent carbon atoms, can be taken together with the carbon atom(s) to which they are attached to form an optionally substituted cycloalkyl or a heterocycloalkyl; wherein:
each instance of Rn3 is independently hydrogen, an optionally substituted —C1-C6 alkyl, or a nitrogen protecting group;
each instance of Ro6 is independently hydrogen, an optionally substituted —C1-C6 alkyl, or an oxygen protecting group; and
each instance of Ro4 is an optionally substituted —C1-C6 alkyl;
each instance of Rs2 is independently an optionally substituted —C1-C6 alkyl or a sulfur protecting group;
Rn6 is hydrogen, an optionally substituted —C1-C6 alkyl, or a nitrogen protecting group; and
q is 0, 1, 2, or 3.

### Claim 44 (depends on 43)

The compound of claim 43, or a pharmaceutically acceptable salt thereof, wherein Rn6 is hydrogen or a —C1-4 alkyl, and Rp is independently hydrogen, halogen, optionally substituted C1-4 alkyl, —CN, —NO2, —N3, —ORo4, —N(Rn2)2, —C(═O)N(Rn2)2, —C(═O)Ro3, or —C(═O)ORo4.

### Claim 45 (depends on 43)

The compound of claim 43, or a pharmaceutically acceptable salt thereof, wherein Q is selected from the following:
and each instance of Rn is independently hydrogen, a halogen, —CN, —NO2, —N3, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted heteroaryl, —ORo4, —SRs1, —N(Rn2)2, —C(═O)N(Rn2)2, —N(Rn2)C(═O)Ro3, —C(═O)Ro3, —C(═O)ORo4, —OC(═O)Ro3, —S(═O)Rs1, —S(═O)2Rs1, —S(═O)ORo4, —OS(═O)Ro3, —S(═O)2ORo4, —OS(═O)2Ro3, —S(═O)N(Rn2)2, —S(═O)2N(Rn2)2, —N(Rn2)S(═O)Rs1, —N(Rn2)S(═O)2Rs1, —N(R2)C(═O)ORo4, —OC(═O)N(Rn2)2, —N(Rn2)C(═O)N(Rn2)2, —N(Rn2)S(═O)N(Rn2)2, —N(Rn2)S(═O)2N(Rn2)2, —N(Rn2)S(═O)ORo4, —N(Rn2)S(═O)2ORo4, —OS(═O)N(Rn2)2, or —OS(═O)2N(Rn2)2; or two instances of Rn attached to the same or adjacent carbon atoms, taken together with the carbon atoms to which they are attached to form an optionally substituted cycloalkyl or a heterocycloalkyl; wherein:
each instance of Rn2 is independently hydrogen, an optionally substituted —C1-C6 alkyl, or a nitrogen protecting group;
each instance of Ro4 is independently hydrogen, an optionally substituted —C1-C6 alkyl, or an oxygen protecting group;
each instance of Ro3 is independently an optionally substituted —C1-C6 alkyl;
each instance of Rs1 is independently an optionally substituted —C1-C6 alkyl or a sulfur protecting group; and
n is 0, 1, 2, or 3, as valency permits.

### Claim 46 (depends on 45)

The compound claim 45, or a pharmaceutically acceptable salt thereof, wherein each instance of Rn is independently hydrogen, halogen, optionally substituted C1-4 alkyl, —CN, —NO2, —N3, —ORo4, —N(Rn2)2, —C(═O)N(Rn2)2, —C(═O)Ro3, or —C(═O)ORo4.

### Claim 47 (depends on 43)

The compound of claim 43, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or a —C1-C4 alkyl.

### Claim 48 (depends on 47)

The compound of claim 47, or a pharmaceutically acceptable salt thereof, wherein R1 is methyl.

### Claim 49 (depends on 43)

The compound of claim 43, or a pharmaceutically acceptable salt thereof, wherein Rj and Rk are each independently hydrogen, a halogen, —ORo7, or a —C1-C4 alkyl, or Rj and Rk are joined together to form ═O.

### Claim 50 (depends on 49)

The compound of claim 49, or a pharmaceutically acceptable salt thereof, wherein Rj and Rk are each hydrogen.

### Claim 51 (depends on 43)

The compound of claim 43, or a pharmaceutically acceptable salt thereof, wherein Ra and Rb are each hydrogen.

### Claim 52 (depends on 43)

The compound of claim 43, or a pharmaceutically acceptable salt thereof, wherein q is 0 or 1, and n is 0 or 1.

### Claim 53 (depends on 43)

The compound of claim 43, or a pharmaceutically acceptable salt thereof, wherein the compound is:

### Claim 54 (depends on 43)

A pharmaceutical composition comprising an effective amount of the compound of claim 43, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 55 (depends on 53)

A pharmaceutical composition comprising an effective amount of the compound of claim 53, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
